NeoStem Announces UCSF Presentation of Phase 1 Results for T Regulatory Cell Immunotherapy for Type 1 Diabetes at American Diabetes Association Annual Meeting

NEW YORK, June 16, Jun 16, 2014 (GLOBE NEWSWIRE via COMTEX) Preliminary Data Indicate Safety and Tolerability in Adult Patients and Complement Recently Published 12-Month Data Indicating Feasibility and Potential Efficacy in Children With T1DM Initiation of Phase 2 Study Expected for Q3 2014 NeoStem, Inc. (Nasdaq:NBS) ( NeoStem or the Company ), a leader in the emerging cellular therapy industry, today announced the presentation of the results of an open-label dose escalation Phase 1 clinical study of autologous T regulatory cell (Treg) immunotherapy for type 1 diabetes mellitus (T1DM) indicating safety and tolerability following administration. This study, funded by the Juvenile Diabetes Research Foundation and conducted by Dr. Stephen Gitelman at University of California, San Francisco (UCSF) and Dr. Kevan Herold at Yale University, provides preliminary data that support developing a novel therapy for the treatment of T1DM with the goal of inducing immune tolerance and preserving pa
http://bit.ly/1ju9Xgl